Alexander Nitschmann
YOU?
Author Swipe
View article: P11.38.A PROGNOSTIC VALUE OF DYNAMIC BRAIN METASTASIS METRICS IN PATIENTS RECEIVING MULTIPLE COURSES OF STEREOTACTIC RADIOTHERAPY
P11.38.A PROGNOSTIC VALUE OF DYNAMIC BRAIN METASTASIS METRICS IN PATIENTS RECEIVING MULTIPLE COURSES OF STEREOTACTIC RADIOTHERAPY Open
BACKGROUND Optimizing the timing of repeat focal radiosurgery versus transition to whole-brain radiotherapy (WBRT) in patients with brain metastases remains unresolved. Traditional static indices like the Diagnosis-Specific Graded Prognost…
View article: Validation of SUV thresholds in [¹⁸F]SiTATE PET/CT for accurate meningioma segmentation
Validation of SUV thresholds in [¹⁸F]SiTATE PET/CT for accurate meningioma segmentation Open
Purpose Somatostatin receptor (SSTR)-targeted PET/CT provides valuable clinical insights beyond standard imaging in meningioma patients. Due to its excellent diagnostic capabilities and favorable logistics, the 18 F-labeled SSTR-targeting …
View article: Evaluating large language models as an educational tool for meningioma patients: patient and clinician perspectives
Evaluating large language models as an educational tool for meningioma patients: patient and clinician perspectives Open
Background The study explores the potential of ChatGPT, an advanced large language model (LLM) by OpenAI, in educating patients about meningioma, a common type of brain tumor. While ChatGPT has generated significant debate regarding its ut…
View article: Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06)
Dummy run for planning of isotoxic dose-escalated radiation therapy for glioblastoma used in the PRIDE trial (NOA-28; ARO-2024-01; AG-NRO-06) Open
NCT05871021.
View article: Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome
Additive value of [18F]PI-2620 perfusion imaging in progressive supranuclear palsy and corticobasal syndrome Open
Purpose Early after [ 18 F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [ 18 F]PI-2620 tau-PET is able to dis…
View article: <sup>18</sup>F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy
<sup>18</sup>F-PI-2620 Tau PET Improves the Imaging Diagnosis of Progressive Supranuclear Palsy Open
Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy movement disorder that can be imaged by the 18F-labeled tau PET tracer 2-(2-([18F]fluoro)pyridin-4-yl)-9H-pyrrolo[2,3-b:4,5-c']dipyridine (18F-PI-2620). The in vivo diagnosis is …
View article: Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies
Additive value of [18F]PI-2620 perfusion imaging in four-repeat tauopathies Open
Purpose Early after [ 18 F]PI-2620 PET tracer administration, perfusion imaging has potential for regional assessment of neuronal injury in neurodegenerative diseases. This is while standard late-phase [ 18 F]PI-2620 tau-PET is able to dis…
View article: Feasibility of short imaging protocols for [<sup>18</sup>F]PI‐2620 tau‐PET in progressive supranuclear palsy
Feasibility of short imaging protocols for [<sup>18</sup>F]PI‐2620 tau‐PET in progressive supranuclear palsy Open
Background Dynamic 60‐minute positron‐emission‐tomography (PET) imaging with the novel tau radiotracer [ 18 F]PI‐2620 facilitated accurate discrimination between patients with progressive supranuclear palsy (PSP) and healthy controls (HCs)…
View article: Binding characteristics of [<sup>18</sup>F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET
Binding characteristics of [<sup>18</sup>F]PI-2620 distinguish the clinically predicted tau isoform in different tauopathies by PET Open
The novel tau-PET tracer [ 18 F]PI-2620 detects the 3/4-repeat-(R)-tauopathy Alzheimer’s disease (AD) and the 4R-tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP). We determined whether [ 18 F]PI-2620 binding…
View article: Cortical [<scp><sup>18</sup>F</scp>]<scp>PI</scp>‐2620 Binding Differentiates Corticobasal Syndrome Subtypes
Cortical [<span><sup>18</sup>F</span>]<span>PI</span>‐2620 Binding Differentiates Corticobasal Syndrome Subtypes Open
Background Corticobasal syndrome is associated with cerebral protein aggregates composed of 4‐repeat (~50% of cases) or mixed 3‐repeat/4‐repeat tau isoforms (~25% of cases) or nontauopathies (~25% of cases). Objectives The aim of this sing…
View article: Feasibility of Short Imaging Protocols for [18F]PI-2620 Tau-PET in Progressive Supranuclear Palsy
Feasibility of Short Imaging Protocols for [18F]PI-2620 Tau-PET in Progressive Supranuclear Palsy Open
PurposeDynamic 60-minute positron-emission-tomography (PET) imaging with the novel tau radiotracer [18F]PI-2620 facilitated accurate discrimination between patients with progressive supranuclear palsy (PSP) and healthy controls (HCs). This…
View article: In Vivo Assessment of Neuroinflammation in <scp>4‐Repeat</scp> Tauopathies
In Vivo Assessment of Neuroinflammation in <span>4‐Repeat</span> Tauopathies Open
Background Neuroinflammation has received growing interest as a therapeutic target in neurodegenerative disorders, including 4‐repeat tauopathies. Objectives The aim of this cross‐sectional study was to investigate 18 kDa translocator prot…
View article: In vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies
In vivo Assessment of Neuroinflammation in 4-Repeat Tauopathies Open
Objective The aim of this cross-sectional single center study was to investigate 18kDa translocator protein (TSPO)-PET as a biomarker for microglial activation in the 4-repeat tauopathies corticobasal degeneration and progressive supranucl…
View article: Assessment of <sup>18</sup>F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy
Assessment of <sup>18</sup>F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy Open
This multicenter evaluation indicates a value of 18F-PI-2620 to differentiate suspected patients with PSP, potentially facilitating more reliable diagnosis of PSP.
View article: Early-phase [F-18]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury
Early-phase [F-18]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury Open
Purpose Second-generation tau radiotracers for use with positron emission tomography (PET) have been developed for visualization of tau deposits in vivo. For several β-amyloid and first-generation tau-PET radiotracers, it has been shown th…